These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 26871934)
1. Scaffold Hopping Approach to a New Series of Pyridine Derivatives as Potent Inhibitors of CDK2. Xu X; Yao Q Arch Pharm (Weinheim); 2016 Mar; 349(3):224-31. PubMed ID: 26871934 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors. Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285 [TBL] [Abstract][Full Text] [Related]
3. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity. Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976 [TBL] [Abstract][Full Text] [Related]
4. Discovery of novel CDK inhibitors via scaffold hopping from CAN508. Jing L; Tang Y; Xiao Z Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093 [TBL] [Abstract][Full Text] [Related]
5. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Maher M; Kassab AE; Zaher AF; Mahmoud Z Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors. Baltus CB; Jorda R; Marot C; Berka K; Bazgier V; Kryštof V; Prié G; Viaud-Massuard MC Eur J Med Chem; 2016 Jan; 108():701-719. PubMed ID: 26741853 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents. Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191 [TBL] [Abstract][Full Text] [Related]
9. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies. Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors. Kuo GH; Deangelis A; Emanuel S; Wang A; Zhang Y; Connolly PJ; Chen X; Gruninger RH; Rugg C; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV J Med Chem; 2005 Jul; 48(14):4535-46. PubMed ID: 15999992 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity. Diao PC; Lin WY; Jian XE; Li YH; You WW; Zhao PL Eur J Med Chem; 2019 Oct; 179():196-207. PubMed ID: 31254921 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors. Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192 [TBL] [Abstract][Full Text] [Related]
13. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors. Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors. Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors. Oudah KH; Najm MAA; Samir N; Serya RAT; Abouzid KAM Bioorg Chem; 2019 Nov; 92():103239. PubMed ID: 31513938 [TBL] [Abstract][Full Text] [Related]
16. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9. Yan L; Lai F; Chen X; Xiao Z Bioorg Med Chem Lett; 2015 Jun; 25(11):2447-51. PubMed ID: 25908517 [TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors. Lee J; Kim KH; Jeong S Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors. Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110 [TBL] [Abstract][Full Text] [Related]
19. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors. Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors. Lu X; Zhang H; Li X; Chen G; Li QS; Luo Y; Ruan BF; Chen XW; Zhu HL Bioorg Med Chem; 2011 Nov; 19(22):6827-32. PubMed ID: 22000948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]